Brand-name Tarceva (erlotinib) is currently protected from generic competition. The first patent for the drug is set to expire in November 2018; this would be the earliest predictable date a generic version could become available, provided there are no lawsuits or other circumstances to extend or shorten the exclusivity period.
Tarceva® (erlotinib) is a prescription medication approved to treat late-stage non-small cell lung cancer and pancreatic cancer. It belongs to a group of medicines known as tyrosine kinase inhibitors.
Tarceva is made Schwarz Pharma Manufacturing for OSI Pharmaceuticals, Inc. It is distributed by Genentech USA, Inc. It is currently under the protection of patents and exclusivity rights that prevent any generic Tarceva from being manufactured in the United States.
The first patent for Tarceva will expire in November 2018. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten this exclusivity period, such as lawsuits or other patents for specific Tarceva uses. Once the patent expires, several companies may start manufacturing a generic Tarceva drug.
No, erlotinib is the active ingredient in Tarceva, but is not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.